PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma
Authors:
Open Access
- 15 April 2024
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 155 (2) , 203-210
Abstract
Metastatic melanoma is still a difficult‐to‐treat cancer type owing to its frequent resistance mechanisms to targeted and immunotherapy. Therefore, we aimed to unravel novel therapeutic strategies for melanoma patients. Preclinical and clinical studies show that melanoma patients may benefit from a treatment with poly (ADP‐ribose) polymerase (PARP) inhibitors (PARPi). In this study, we focus on PARP1 as a potential biomarker to predict the response of melanoma cells to PARPi therapy. We found that melanoma cells with high basal PARP1 expression exhibit significantly increased cell death after PARPi treatment owing to higher PARP1 trapping compared with melanoma cells with low PARP1 expression. In addition, we could demonstrate that PARP1 expression levels are low in nonmalignant skin cells, and metastatic melanomas show considerably higher PARP1 levels compared with primary melanomas. Most strikingly, we found that high PARP1 levels correlate with worse overall survival of late stage metastasized melanoma patients. In conclusion, we show that PARP1 might act as a biomarker to predict the response to PARPi therapy, and that in particular the late stage metastasized melanoma patients are especially sensitive to PARPi therapy owing to elevated PARP1 expression. Our data suggest that the PARPi cytotoxicity primarily will affect the high PARP1 expressing melanoma cells, rather than the low PARP1 expressing nonmalignant skin cells resulting in only low side effects.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (RTG2816, SCHI510/12‐1)
This publication has 15 references indexed in Scilit:
- PARP1 Is a Prognostic Marker and Targets NFATc2 to Promote Carcinogenesis in MelanomaGenetic Testing and Molecular Biomarkers, 2022
- PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway ComponentsOncoTargets and Therapy, 2022
- Treatment of Advanced Melanoma in 2020 and BeyondJournal of Investigative Dermatology, 2021
- Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosisPathology - Research and Practice, 2020
- PARP1: A potential biomarker for gastric cancerPathology - Research and Practice, 2019
- PARP-1 Expression Quantified by [ 18 F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation TherapyCancer Biotherapy and Radiopharmaceuticals, 2017
- PARP-1 Regulates Metastatic Melanoma through Modulation of Vimentin-induced Malignant TransformationPLOS Genetics, 2013
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicCA: A Cancer Journal for Clinicians, 2011
- Melanoma biology and new targeted therapyNature, 2007